登革热疫苗TAK-003的接种策略、公共卫生影响与成本效果:泰国建模案例研究
本研究建立包含宿主与媒介种群、4种血清型感染和季节性的动态传播模型,以泰国为案例评估登革热疫苗TAK-003的公共卫生影响与成本效果。
要点
- TAK-003可预防41%-57%的症状性病例和47%-70%的住院。
核心结论
- TAK-003可大幅降低泰国登革热负担并带来成本节省。
- 通过确定最佳接种年龄队列并增加追赶程序,可最大化这些效益。
- 该模型可用于评估其他登革热流行国家的接种影响。
研究设计与样本
- 建立包含宿主与媒介种群、4种血清型感染、季节性和登革热自然史其他关键要素的动态传播模型。
- 从DEN-301试验估计TAK-003的效力。
- 基于泰国登革热流行病学,先用模型确定不同接种策略下TAK-003的最佳队列年龄。
- 评估将TAK-003纳入泰国现有国家免疫规划的务实策略的公共卫生影响。
- 从社会视角使用伤残调整生命年(DALY)在20年时间范围内评估成本效果。
主要发现
- TAK-003估计可预防41%-57%的症状性病例和47%-70%的住院。
- 敏感性分析表明结果稳健。
关键数值与推荐
- TAK-003估计可预防41%-57%的症状性病例和47%-70%的住院。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性在于模型中所做的假设和简化,这些在近似真实世界接种影响时不可避免。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is an increasing global problem associated with negative health and economic impacts. Vaccination is an important measure to reduce the significant public health and economic burden caused by dengue. Our study assesses the public health impact and cost-effectiveness of a new dengue vaccine, TAK-003, using Thailand as a case study. METHODS AND FINDINGS: We developed a dynamic transmission model with both host and vector populations, 4 serotype-specific infections, seasonality, and other key elements of dengue natural history. We estimated efficacy of TAK-003 from the DEN-301 trial. We first used the model to determine the optimal cohort age for different vaccination strategies with TAK-003, based on Thai dengue epidemiology. Secondly, we assessed the public health impact of a pragmatic strategy integrating TAK-003 into an existing national immunization program in Thailand. Cost-effectiveness was evaluated from a societal perspective using disability-adjusted life-years (DALYs) over a 20-year horizon. TAK-003 is estimated to prevent 41%-57% of symptomatic cases and 47%-70% of hospitalizations, with the greatest impact observed when routinely vaccinating children aged 6 years with 10 additional catch-up cohorts. This strategy resulted in 104,415 fewer DALYs and savings of US$1,786 million. If introduced into the national immunization program at 11 years of age (alongside the existing human papillomavirus vaccine), TAK-003 is estimated to prevent 44% of symptomatic cases and 53% of hospitalizations. This strategy prevented 87,715 DALYs and saved US$1,346 million. Sensitivity analyses demonstrated that the results were robust. The main limitations were inherent to the assumptions and simplifications made in the model, which are unavoidable when approximating the impact of vaccination in the real world. CONCLUSIONS: TAK-003 can considerably reduce dengue burden and lead to cost savings in Thailand. These benefits can be maximized by identifying optimal age cohorts for vaccination and adding catch-up programs. Our model can be used to assess the vaccination impact in other dengue-endemic countries.
引用
- Shen J, Kharitonova E, Tytula A, et al. Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. PLoS Med. 2025. PMID: 40526690. doi:10.1371/journal.pmed.1004631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。